VIR has been the topic of a number of other reports. TheStreet lowered shares of Vir Biotechnology from a “c-” rating to a “d+” rating in a research note on Monday, March 28th. Needham & Company LLC lowered their price objective on Vir Biotechnology from $80.00 to $45.00 and set a “buy” rating for the company in a research report on Monday, March 28th. Zacks Investment Research upgraded Vir Biotechnology from a “strong sell” rating to a “hold” rating in a research note on Friday, May 6th. Finally, Robert W. Baird raised shares of Vir Biotechnology from an “underperform” rating to a “neutral” rating and decreased their price target for the stock from $36.00 to $28.00 in a research report on Thursday, March 3rd. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, Vir Biotechnology currently has a consensus rating of “Hold” and a consensus price target of $56.57.
Vir Biotechnology stock opened at $19.08 on Thursday. The company’s fifty day moving average price is $23.03 and its 200 day moving average price is $31.69. Vir Biotechnology has a 1 year low of $18.84 and a 1 year high of $58.00. The stock has a market capitalization of $2.53 billion, a P/E ratio of 2.11, a P/E/G ratio of 0.42 and a beta of -0.55.
In other Vir Biotechnology news, Director Vicki L. Sato sold 14,541 shares of Vir Biotechnology stock in a transaction dated Monday, May 9th. The shares were sold at an average price of $20.62, for a total value of $299,835.42. Following the sale, the director now owns 1,503,463 shares of the company’s stock, valued at $31,001,407.06. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Vicki L. Sato sold 17,915 shares of the business’s stock in a transaction that occurred on Thursday, April 28th. The shares were sold at an average price of $20.90, for a total transaction of $374,423.50. Following the completion of the sale, the director now directly owns 1,518,004 shares in the company, valued at approximately $31,726,283.60. The disclosure for this sale can be found here. Insiders have sold 56,168 shares of company stock valued at $1,411,832 in the last three months. Insiders own 22.40% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in VIR. Point72 Asset Management L.P. lifted its holdings in Vir Biotechnology by 9,370.5% in the 4th quarter. Point72 Asset Management L.P. now owns 2,055,100 shares of the company’s stock worth $86,047,000 after purchasing an additional 2,033,400 shares in the last quarter. Millennium Management LLC lifted its holdings in Vir Biotechnology by 485.9% during the fourth quarter. Millennium Management LLC now owns 967,825 shares of the company’s stock valued at $40,523,000 after purchasing an additional 802,652 shares in the last quarter. Norges Bank acquired a new stake in shares of Vir Biotechnology in the fourth quarter valued at about $20,827,000. Alliancebernstein L.P. raised its stake in Vir Biotechnology by 22.6% during the fourth quarter. Alliancebernstein L.P. now owns 2,620,753 shares of the company’s stock worth $109,731,000 after purchasing an additional 483,261 shares during the period. Finally, Qube Research & Technologies Ltd acquired a new position in Vir Biotechnology in the first quarter valued at approximately $8,460,000. Institutional investors and hedge funds own 79.91% of the company’s stock.
Vir Biotechnology Company Profile (Get Rating)
Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.
- Get a free copy of the StockNews.com research report on Vir Biotechnology (VIR)
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
- Wolverine Worldwide Is Ready To Rebound
- Wendy’s Growth Story Has Come To An End
- Beyond Meat Could Sizzle After Q1 Results Are Released
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.